Class summary at a glance.

Every drug in the HMG-CoA Reductase Inhibitor (Statin) class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $199.2Mcombined across class
Total Rx claims: 14.0M4.4M unique beneficiaries
Generic mfrs (active): 15across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Pravastatin

13.9M Part D claims (CY24) · 4.4M beneficiaries · First FDA approval: 2006-04-25

12 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.060

→

Avg plan cost$0.085

Part D spend $188.5M 1× spread, current vs floor

Class share

95%

of class CY24 spend

View profile →

Fluvastatin

Brand: Lescol · 59K Part D claims (CY24) · 20K beneficiaries · First FDA approval: 2000-10-06

3 generic mfrs 0 plans require PA Discontinued

Low NADAC$2.54

→

Avg plan cost$3.47

Part D spend $10.7M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.